Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
FOMX was delisted on the 6th of March, 2020.
56 hedge funds and large institutions have $110M invested in Foamix Pharmaceuticals Ltd. Ordinary Shares in 2018 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 15 increasing their positions, 14 reducing their positions, and 7 closing their positions.
114% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 7
17% more funds holding
Funds holding: 48 → 56 (+8)
7% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 14
8% less call options, than puts
Call options by funds: $833K | Put options by funds: $904K
15% less capital invested
Capital invested by funds: $130M → $110M (-$19.9M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$6.62M |
| 2 |
DM
Deerfield Management
New York
|
+$1.04M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$781K |
| 4 |
Barclays
London,
United Kingdom
|
+$667K |
| 5 |
EP
Eversept Partners
New York
|
+$647K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$5.22M |
| 2 |
SAM
Senzar Asset Management
New York
|
-$2.27M |
| 3 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
-$1.92M |
| 4 |
Jennison Associates
New York
|
-$1.91M |
| 5 |
SCM
Sio Capital Management
New York
|
-$789K |
FOMX Hedge Fund Activity: Q1 2018 in Review
56 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) for Q1 2018, worth a combined $110M — down 15% from $130M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new FOMX positions and 7 closed out — a net gain of 8 holders — while 15 added to existing stakes and 14 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $6.62M. The largest seller was Baker Bros. Advisors, cutting an estimated $5.22M.
- 56 institutional investors held Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) as of Q1 2018, up from 48 in Q4 2017.
- Funds reported $110M of Foamix Pharmaceuticals Ltd. Ordinary Shares stock for Q1 2018, down 15% quarter-over-quarter.
- 15 funds opened new Foamix Pharmaceuticals Ltd. Ordinary Shares positions in Q1 2018 and 7 closed out, a net change of +8 holders.
- The largest Foamix Pharmaceuticals Ltd. Ordinary Shares buyer in Q1 2018 was OrbiMed, an estimated $6.62M added.
- The largest Foamix Pharmaceuticals Ltd. Ordinary Shares seller in Q1 2018 was Baker Bros. Advisors, an estimated $5.22M sold.
Based on aggregated 13F filings for Q1 2018.